Cardiac Allograft Vasculopathy
3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Verona PharmaUK - London
1 program1
Everolimus-Eluting Bioresorbable Vascular ScaffoldPhase 41 trial
Active Trials
Allergy TherapeuticsUK - West Sussex
1 program1
Rituximab induction/conventional immunosuppressionPhase 2
GenentechCA - Oceanside
1 program1
Rituximab induction/conventional immunosuppressionPhase 21 trial
Active Trials
Novo NordiskBAGSVAERD DENMARK, Denmark
1 programCardiac Mitochondrial Function After Heart TransplantationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Verona PharmaEverolimus-Eluting Bioresorbable Vascular Scaffold
GenentechRituximab induction/conventional immunosuppression
Novo NordiskCardiac Mitochondrial Function After Heart Transplantation
Clinical Trials (3)
Total enrollment: 460 patients across 3 trials
Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy
Start: Jan 2015Est. completion: Dec 202034 patients
Phase 4Completed
Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation
Start: Sep 2011Est. completion: Oct 2015362 patients
Phase 2Terminated
Cardiac Mitochondrial Function After Heart Transplantation
Start: Apr 2019Est. completion: Mar 202464 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space